InvestorsHub Logo
Post# of 200778
Next 10
Followers 14
Posts 2740
Boards Moderated 0
Alias Born 05/06/2020

Re: Godough post# 161649

Tuesday, 05/11/2021 4:10:11 PM

Tuesday, May 11, 2021 4:10:11 PM

Post# of 200778
So I spy with my minds eye..

Keep in mind PCTL was TOLD of this process, a process they (we) had to live with.

PCTL PR 1/29/21
https://www.para-con.com/images/docs/PCTL01-29-21.pdf

From EDGAR (same)
https://www.sec.gov/Archives/edgar/data/1119897/000155479521000130/pctl0405form10kexh99_09.htm

Hmmmmm, not just Covid, BUT HAI's too!


In a recent communication to Mr. Barry Dunn, Managing Director of PCT (Europe) Ltd, PCTL was informed that North Tees Hospital has successfully completed its first phases of testing the Annihilyzer® and will now begin a robust 12 week evaluation study on several live and occupied Wards, including one dedicated to COVID-19 patients. The Hospital will commence the final evaluation of PCTL’s Annihilyzer® on the live Wards following initial results that provided the evidence needed to allow the Hospital’s Infection Control Director to authorize the final phase of testing. This live study will be fully supported by the Infection Control and Operational Decontamination Cleaning Teams.

The final stage of the study will utilize the National Institute of Health Research (NIHR) protocols, which will be clinically sponsored by Teesside University’s Microbiology Department. The eight (8) fully patient occupied Wards being used for the study have been subject to COVID-19 outbreaks and regular Hospital Associated Infections (HAI’s).

The University will assist in the collection of base line and pre-evaluation information collected during and post-evaluation to ensure a broad representation of data, which will be published in support of the system and the HOCl fluids it generates.



Note;
Mr. Barry Dunn is the Managing Director of PCT (Europe) Ltd